Related Experiment Video
Updated: May 4, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Economic impact of a triptan Rx-to-OTC switch in six EU countries
Aurelie Millier1, Joshua Cohen2, Mondher Toumi3
1Health Economics and Outcomes Research Department, Creativ-Ceutical, Paris, France.
Introduction:
Triptans have been safely and effectively used in the management of migraine for more than fifteen years, and it seems reasonable to wonder what would be the economic impact of moving a specific triptan to OTC availability. The objective of this study was then to examine the economic impact of payer policies of a triptan Rx-to-OTC switch in six EU countries (France, UK, Spain, Italy, Germany and Poland).
Methods:
A decision model was used to model the budgetary impact of a triptan Rx-to-OTC switch from the third-party payer (TPP) and the societal perspectives, using a one-year timeframe.
Results:
From the TPP perspective, it is estimated that the current overall direct spending on the management of migraine attacks across the 6 EU Member States is €582 million annually, and that the savings would reach €75 million (13% of the overall direct economic burden of migraine). From the societal perspective, €86 million annually would be added.
Conclusions:
Given evidence of effectiveness and safety, and given the potential savings, a triptan Rx-to-OTC switch is a reasonable public policy decision.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Bioequivalence of Drugs: Drugs with Multiple Indications
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Delivery: Enteral Route
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drug Products: Biologics, Biosimilars and Interchangeables

